| Patients enrolled at baseline | Patients enrolled after two cycles treatment |
---|---|---|
 | (n=134) | (n=121) |
Age | Â | Â |
Median (range), years | 64 (34-74) | 64 (34-74) |
  ≥65 years | 79 (59%) | 67 (55%) |
  <65 years | 55 (41%) | 54 (45%) |
Sex | Â | Â |
  Male | 128 (96%) | 116 (96%) |
  Female | 6 (4%) | 5 (4%) |
Smoking history | Â | Â |
  ≥400 cigarette-years | 117 (87%) | 107 (88%) |
  <400 cigarette-years | 6 (4%) | 5 (4%) |
Never | 11 (9%) | 9 (8%) |
ECOG performance status | ||
  0 | 25 (19%) | 21 (17%) |
  1 | 109 (81%) | 100 (83%) |
Disease stage | Â | Â |
  IIIB/IIIC | 40 (30%) | 34 (28%) |
  IV | 94 (70%) | 87 (72%) |
  Liver or brain metastases at enrollment* | 0 (0%) | 0 (0%) |
  Liver metastases | 14 (10%) | 14 (12%) |
  Brain metastases | 2 (1%) | 2 (2%) |
PD-L1 tumor proportion score | ||
  <1% | 61 (46%) | 57 (47%) |
  ≥1% | 70 (52%) | 61 (50%) |
  1-49% | 36 (27%) | 37 (31%) |
  ≥50% | 34 (25%) | 24 (20%) |
Not evaluable | 3 (2%) | 3 (2%) |